tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Guardian Pharmacy Reaffirms 2025 Outlook, Issues 2026 Guidance

Story Highlights
  • Guardian reaffirmed 2025 guidance and issued a 2026 outlook showing revenue pressure from drug-price reforms but stronger profitability and margin expansion.
  • The company expects low double-digit adjusted EBITDA growth in 2026 and has expanded into Montana with a new pharmacy acquisition to support its long-term care platform.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Guardian Pharmacy Reaffirms 2025 Outlook, Issues 2026 Guidance

Claim 70% Off TipRanks Premium

Guardian Pharmacy Services, Inc. Class A ( (GRDN) ) has shared an update.

Guardian Pharmacy Services, a major U.S. long-term care pharmacy operator, reaffirmed its 2025 revenue guidance of $1.43 billion to $1.45 billion and adjusted EBITDA guidance of $104 million to $106 million, while issuing an initial 2026 outlook that anticipates revenue of $1.40 billion to $1.42 billion after the impact of Inflation Reduction Act drug-pricing reforms and wholesale acquisition cost reductions. Despite the expected top-line pressure from these mandatory pricing changes, the company projects 2026 adjusted EBITDA of $115 million to $118 million—about 11% year-on-year growth and implying an adjusted EBITDA margin above 8%—and highlighted that its strengthened operating model should allow it to maintain its low double-digit adjusted EBITDA growth trajectory without altering its approach to resident care or facility support; Guardian also disclosed it had completed the year-end acquisition of a single pharmacy in Montana, extending its geographic footprint into a new territory in line with its expansion strategy.

The most recent analyst rating on (GRDN) stock is a Hold with a $30.00 price target. To see the full list of analyst forecasts on Guardian Pharmacy Services, Inc. Class A stock, see the GRDN Stock Forecast page.

Spark’s Take on GRDN Stock

According to Spark, TipRanks’ AI Analyst, GRDN is a Neutral.

Guardian Pharmacy Services shows strong growth potential with increased guidance and strategic acquisitions. However, financial risks due to high leverage and operational inefficiencies, combined with a high P/E ratio, temper the overall attractiveness of the stock.

To see Spark’s full report on GRDN stock, click here.

More about Guardian Pharmacy Services, Inc. Class A

Guardian Pharmacy Services (NYSE: GRDN) is one of the nation’s leading long-term care pharmacy services providers, partnering with long-term care facilities through a locally based model to deliver medications and technology-enabled services that enhance care, improve adherence, reduce costs, and support better clinical outcomes. The company operates a growing network of more than 50 pharmacies across the U.S., serving approximately 204,000 residents as of September 30, 2025.

Average Trading Volume: 310,308

Technical Sentiment Signal: Strong Buy

Current Market Cap: $1.92B

See more insights into GRDN stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1